Random Questions

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

miamidoc2b

Full Member
20+ Year Member
Joined
Dec 16, 2004
Messages
501
Reaction score
84
Just had some questions and wanted to get some input!

When a nerve stimulator is placed to check for TOF, etc., where exactly is it placed i.e. axon, myoneural junction, etc.?

Also, which releases more histamine : meperidine or morphine?
 
Good questions. I don't know the answers off the top of my head...
 
Just had some questions and wanted to get some input!

When a nerve stimulator is placed to check for TOF, etc., where exactly is it placed i.e. axon, myoneural junction, etc.?

Also, which releases more histamine : meperidine or morphine?

You usually and ideally place your nerve stimulator over the path of some peripheral nerve but I am sure some of your current could be entering the neuromuscular junction directly as well.

Morphine causes more Histamine release the Meperidine.
 
Histamine Release by Four Narcotics

A Double-Blind Study in Humans

Joan W. Flacke, MD, Werner E. Flacke, MD, Byron C. Bloor, PhD, Aaron P. Van Etten, MS, and Benjamin J. Kripke, MD

[SIZE=-1]Received from the Department of Anesthesiology, University of California, Los Angeles, Center for the Health Sciences, Los Angeles, California. [/SIZE]
[SIZE=+1]Abstract[/SIZE] Histamine release and hemodynamic changes associated with four narcotics were studied in 60 adults (28 men, 32 women) scheduled for general surgery under balanced anesthesia. Under double-blind conditions, incremental eauipotent doses of meperidine, morphine, fentanyl, or sufentanil were administered IV for induction of anesthesia, prior to thiopental, succinylcholine, and intubation. Arterial blood samples were drawn before and 1, 6, and 20 min after narcotic administration. Of the 16 patients given meperidine (mean dose 4.3 ± 0.2 (SEM) mg/kg), five (31%) had clinical signs (hypotension, tachycardia, erythema) and elevations in plasma histamine levels ranging from 3.2 to 49.7 µg/ml 1 min after narcotic administration. Plasma epinephrine levels at this time were also elevated in these five patients. One of the ten patients given morphine (0.6 ± 0.02 mg/kg) developed hypotension, tachycardia, and an increase in plasma histamine level to 12.4 ng/ml. None of 34 patients given either fentanyl (7 ± 0.4 µg/kg) or sufentanil (1.3 ± 0.1 µg/kg) had clinical signs of histamine release or elevations of plasma histamine levels. In the six patients in whom histamine release occurred, there was a significant correlation between the histamine levels at 1 min and the magnitude of change in heart rate, blood pressure, and plasma epinephrine level. All six histamine releasers were young women, ranging in age from 18 to 35 yr. Histamine release occurred more frequently after meperidine than after the other narcotics, including morphine, and the degree of hemodynamic compromise was related to the increase in plasma histamine concentration.
 
Yes, I know this study Blade but I think it's BS!
Over the years I have many times seen clinical signs of histamine release with Morphine but I can't remember one case with Meperidine and I used to give Meperidine very frequently.


Histamine Release by Four Narcotics

A Double-Blind Study in Humans

Joan W. Flacke, MD, Werner E. Flacke, MD, Byron C. Bloor, PhD, Aaron P. Van Etten, MS, and Benjamin J. Kripke, MD

[SIZE=-1]Received from the Department of Anesthesiology, University of California, Los Angeles, Center for the Health Sciences, Los Angeles, California. [/SIZE]
[SIZE=+1]Abstract[/SIZE] Histamine release and hemodynamic changes associated with four narcotics were studied in 60 adults (28 men, 32 women) scheduled for general surgery under balanced anesthesia. Under double-blind conditions, incremental eauipotent doses of meperidine, morphine, fentanyl, or sufentanil were administered IV for induction of anesthesia, prior to thiopental, succinylcholine, and intubation. Arterial blood samples were drawn before and 1, 6, and 20 min after narcotic administration. Of the 16 patients given meperidine (mean dose 4.3 ± 0.2 (SEM) mg/kg), five (31%) had clinical signs (hypotension, tachycardia, erythema) and elevations in plasma histamine levels ranging from 3.2 to 49.7 µg/ml 1 min after narcotic administration. Plasma epinephrine levels at this time were also elevated in these five patients. One of the ten patients given morphine (0.6 ± 0.02 mg/kg) developed hypotension, tachycardia, and an increase in plasma histamine level to 12.4 ng/ml. None of 34 patients given either fentanyl (7 ± 0.4 µg/kg) or sufentanil (1.3 ± 0.1 µg/kg) had clinical signs of histamine release or elevations of plasma histamine levels. In the six patients in whom histamine release occurred, there was a significant correlation between the histamine levels at 1 min and the magnitude of change in heart rate, blood pressure, and plasma epinephrine level. All six histamine releasers were young women, ranging in age from 18 to 35 yr. Histamine release occurred more frequently after meperidine than after the other narcotics, including morphine, and the degree of hemodynamic compromise was related to the increase in plasma histamine concentration.
 
Demerol was originally thought to be a spasmolytic substitute for atropine, but it was soon realized hat the drug possessed analgesic potency. Demerol possesses greater activity when compared to morphine in suppression of secretory activity. Demerol has definite antihistaminic action when compared to morphine. Demerol is known to relax bronchial spasm induced by histamine and other bronchospastic agents.
 
Demerol was originally thought to be a spasmolytic substitute for atropine, but it was soon realized hat the drug possessed analgesic potency. Demerol possesses greater activity when compared to morphine in suppression of secretory activity. Demerol has definite antihistaminic action when compared to morphine. Demerol is known to relax bronchial spasm induced by histamine and other bronchospastic agents.

And tell what, I actually agree with these things.
 
1Opioids


  • Overview


    • Advantages for use in preoperative medication:
      1. Absence of myocardial depressant effects
      2. Alleviate the preoperative pain
      3. Management of discomfort associated with invasive monitor insertion
      4. Management of pain which may be associated with establishing regional anesthetia


    • Preoperative opioids may limit or eliminate the need for supplemental analgesics during the early postoperative phase


      • Pain experienced by lightly anesthetized patients may cause CNS changes that exacerbate pain postoperatively.
        • For example, in support of this hypothesis, a higher opioid concentration is required for suppression of C-fiber activation if pain has caused previous C-fiber activity


    • Generally, in the absence of preoperative pain there may be no compelling reason to include a narcotic for preoperative anesthetic medication.
      • On the other hand, opioid administration to patients experiencing preoperative pain not only relieves pain but also may induce a euphoric state.


  • Commonly used opioids for premedication


    • Most commonly used: morphine and meperidine (Demerol)


      • Morphine:
        • intramuscular injection; good absorption with peak plasma levels obtained in about 45-90 minutes
        • intravenous administration: the effects occur more rapidly, usually within 20 minutes


      • Meperidine (Demerol):
        • Relative to morphine intramuscular injection yields a less predictable time to onset


    • One advantage of including morphine as part of preoperative medication:
      • Morphine tends to suppress tachycardic responses to surgical stimulation during volatile anesthetic administration


  • Contexts for opioid administration:
    • Intramuscular: appropriate for nitrous oxide-opioid anesthesia
    • Intravenous administration: appropriately administered immediately before induction (fentanyl (Sublimaze) is a good choice in this application)


    • Pain associated with regional anesthesia or associated with invasive monitoring catherization or even large intravenous lines may justify treatment with preoperative opioids.
      • As would be expected for many agents, dosage reduction may be required for the elderly patient.
      • Elderly patients may have reduced pain sensitivity that may exhibit an enhanced analgesic response to the opioid


    • Occasionally preoperative opioids are administered in advance of a nitrous oxide-opioid anesthesia plan -- the rationale is that previous opioid administration allows the anesthesia provider to gauge the patients ensuing intraoperative opioid response.
      • For postoperative pain, preoperative opioids may be employed; however, it is probably preferable to either provide administration in to recover room setting or perhaps most appropriately provide IV opioids during the emergence
      • Preoperative opioid administration may lower anesthetic requirements


      • For facemask induction, opioids may be used in combination with other agents-in this case opioid-mediated respiratory depression may decrease ventilation during spontaneous breathing which will reduce the rate of inhalational drug uptake. {the circumstance might arise if for some reason intravenous induction agents may not be used}
        • In this eventuality, the anesthesia provider may have to control ventilation, overcoming opioid-induced respiratory depression


  • Adverse Effects:
    • Minimal cardiovascular effects are noted, except for high-dose meperidine (Demerol)


    • Respiratory depression: associated with reduced responsiveness to CO2 (medullary respiratory center depression)


      • Even low-opioid doses reduce carotid body hypoxia responsiveness -- accordingly, anesthesia providers may wish to administer supplemental oxygen for those patients receiving opioids as premedication
        • The problem of using opioid agonist-antagonist agents, which cause reduced respiratory depression, is that they also are less effective analgesic drugs. Also, these partial agonists may cause dysphoria (instead of the more expected euphoric response), a condition and not desirable in the preoperative time frame -- or probably any other time frame


    • Orthostatic hypotension secondary to peripheral vascular smooth muscle relaxation:
      • Opioids prevent the expected compensatory peripheral vascular vasoconstriction.
      • This effect is in addition to opioid- promoted histamine release that tends to cause a hypotensive reaction.
      • The hypotensive response will be more profound in patients who are hypovolemic.
      • Hypotensive reactions can be avoided by ensuring that patients remained supine following opioids (and other) premedication agents.


    • Nausea & vomiting: These effects are frequently associated with opioid administration, possibly occurring as a result of stimulation of the medullary chemoreceptor trigger zone or vestibular apparatus stimulation leading to motion sickness.
      • The likelihood of nausea and vomiting may be reduced by placing the patient in a recumbent position; however, the use of opioids because of their tendency to cause nausea and vomiting perhaps should be avoided in the same-day outpatient setting or if the surgical procedure's themselves are likely to cause nausea and vomiting {i.e. some gynecological and opthalmological surgeries}
    • Delayed gastric emptying, which is associated with nausea symptoms, has two important consequences-(1) altered absorption rate for orally-administered agents and (2) and increased risk of pulmonary aspiration


    • Opioids may also cause smooth muscle constriction (biliary spasm {choledochododenal sphincter spasm, i.e. sphincter of Oddi}). Manifestation consists of an upper right quadrant pain secondary to smooth muscle constriction
      • Patients with biliary tract disease should perhaps not receive opioids.
      • Also pain associated with biliary spasm, e.g. caused by an opioid, may be difficult to distinguish from angina particularly since pain from either angina or biliary spasm would be relieved by smooth muscle relaxation due to sublingual nitroglycerin.
      • Opioid-induced pain, however, would be relieved by administration of a pure opioid antagonist such as naloxone (Narcan) or naltrexone (ReVia) or possibly glucagon. These drugs would not reverse true anginal pain.
      • Meperidine (Demerol) is less likely than morphine to cause biliary tract spasm.


    • Pruritis-probably secondary to histamine release;
      • Accordingly opioids may cause flushing and dizziness.
      • Since opioids are miotic agents, pinpoint pupils may occur.


  • Specific agents:


    • Morphine:- dosage (5-15 mg, IM Route of Administration)
      • Well absorbed following IM administration


      • Time to onset: 15-30 minutes with peak effect at about 45-90 minutes with total duration of action as long as about four hours
        • With intravenous usage, significant, peak effects occur within about 20 minutes
      • Side reactions as noted for the opioid group in general, including ventilation depression; orthostatic hypotension as well as nausea and vomiting secondary to effects on the chemoreceptor trigger zone (CTZ) or on the vestibular apparatus
      • Reduction in GI motility
      • Preoperative use of morphine reduces cardioacceleration associated with surgical stimulation and volatile anesthetic agents


    • Meperidine (Demerol) dosage: (50-150 mg, IM Route of Administration)
      • Less potent compared to morphine (about 10% as potent)
      • Route of Administration: oral or parenteral
      • Single dosage effect duration: 2-4 hours with intramuscular injection providing a variable time to peak effect and duration
      • Elimination: mainly through hepatic metabolism
      • Cardiovascular effects: positive chronotropic effect secondary to antimuscarinic drug effects.


    • Fentanyl (Sublimaze):dosage-1-2 ug/kg intravenous for preoperative analgesia


      • Alternative Routes of Administration:


        • Oral (transmucosal) fentanyl (Sublimaze)-- 5-20 ug/kg [used in children & adults to diminish preoperative anxiety & pain)
          • Transmucosal fentanyl (Sublimaze) is associated with a high incidence of preoperative gastrointestinal disturbance (nausea & vomiting) typically at doses > 15 ug/kg: Therefore, transmucosal fentanyl (Sublimaze) at these dosages is not recommended for patients < 6 years of age


      • Fentanyl (Sublimaze) issues:
        • Significant respiratory (ventilation) depression
        • Significant bradycardia
        • Fentanyl (Sublimaze) plus benzodiazepines may result in unwanted synergistic effects requiring close observation
        • Histamine release is NOT associated with fentanyl (Sublimaze)
        • Fentanyl (Sublimaze) administration does not cause myocardial depression


    • Agonist-antagonist agents
      • These drugs, e.g. pentazocine (Talwain), butorphanol (Stadol), nalbuphine exhibit reduced respiratory depression compared to pure opioid agonists; however, these drugs also have comparatively limited analgesic effects.
      • These partial agonist, given preoperatively, reduce the efficacy of pure opioid agonist given postoperatively to control postoperative pain. Partial agonist administration can in fact limit or reverse analgesia caused by the presence of the pure agonist


  • 4Side effect incidence following preoperative opioid administration: [1 hr following dosage]-- original citation: Forest, w.H., Brown, B.W. et al.: "Subjective responses to six common preoperative medications", Anesthesiology 47:241, 1977.


    • Morphine (5-10 mg):
      • Dry mouth 80%
      • Slurred speech 33%
      • Dizziness 15%
      • Nausea 7%
      • Relaxation 20%


    • Meperidine (Demerol) (50-100 mg):
      • Dry mouth 85%
      • Slurred speech 45%
      • Dizziness 20%
      • Nausea 12%
      • Relaxation 25%
References:
  • 1Preoperative Medication in Basis of Anesthesia, 4th Edition, Stoelting, R.K. and Miller, R., p 119- 130, 2000)
  • Hobbs, W.R, Rall, T.W., and Verdoorn, T.A., Hypnotics and Sedatives; Ethanol In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc., 1996, pp. 364-367.
  • 3Sno E. White The Preoperative Visit and Premedication in Clinical Anesthesia Practice pp. 576-583 (Robert Kirby & Nikolaus Gravenstein, eds) W.B. Saunders Co., Philadelphia, 1994
  • 4John R. Moyers and Carla M. Vincent Preoperative Medication in Clinical Anethesia, 4th edition (Paul G. Barash, Bruce. F. Cullen, Robert K. Stoelting, eds) Lippincott Williams & Wilkins, Philadelphia, PA, 2001
  • 5Kathleen R. Rosen and David A. Rosen, "Preoperative Medication" pp. 61-70 in Principles and Procedures in Anesthesiology (Philip L. Liu, ed) J. B. Lipincott Company, Philadelphia, 1992
 
Blade the first article doesn't address where exactly the stimulator is placed in terms of microstructures of the nerves.

Interesting about the meperidine releasing more histamine....I wonder if this a well known fact!
 
spacer.gif

[FONT=Times New Roman, Times, serif]DEMEROL® .[FONT=Times New Roman, Times, serif]Sanofi .[FONT=Times New Roman, Times, serif]Meperidine HCl .[FONT=Times New Roman, Times, serif]Analgesic . [FONT=Times New Roman, Times, serif]Action And Clinical Pharmacology:. Meperidine is an opioid analgesic which acts predominantly as a mu-agonist.

In its effects on the CNS, meperidine resembles but is not identical to morphine. Analgesic effects are detectable within about 15 minutes following oral administration, reaching a peak within about 2 hours and subsiding gradually over several hours thereafter. Onset of analgesic effect is faster (within 10 minutes) after s.c. or i.m. administration, reaching a peak within about 1 hour that corresponds closely to the peak concentrations in plasma. In clinical use, the duration of effective analgesia is about 3 to 5 hours. Given parenterally, 75 to 100 mg of meperidine is approximately equivalent to 10 mg of morphine in analgesic effectiveness. At equianalgesic dosage, the 2 agents are comparable in the degree of sedation and of respiratory depression they produce. Given parenterally, meperidine is more than twice as effective as given orally in terms of the total analgesic response obtained. This is consistent with an oral bioavailability of about 40 to 60%.

In its effects on the cardiovascular system, meperidine generally resembles morphine, including its ability to release histamine upon parenteral administration. Heart rate is unlikely to be significantly affected with i.m. administration but may increase, with i.v. administration. As with morphine, respiratory depression leads to an accumulation of carbon dioxide which in turn produces cerebrovascular dilatation, increase in cerebral blood flow and elevation of cerebrospinal fluid pressure.

The effects of meperidine on smooth muscle are qualitatively similar, but in relation to analgesic effect less intense than those of other opioids. Meperidine does not cause as much constipation when given over prolonged periods of time. This may be related to its greater facility to enter the CNS, thereby producing analgesia at lower peripheral concentrations. At equianalgesic dosage, the rise in pressure in the common bile duct induced by meperidine is less than that by morphine, but greater than that by codeine. Clinical doses of meperidine nevertheless slow gastric emptying sufficiently to delay absorption of other drugs significantly. The uterus of nonpregnant women is usually mildly stimulated by meperidine. Therapeutic doses given during active labor do not delay the birth process; in fact, the frequency, duration and amplitude of uterine contractions may sometimes be increased. Meperidine does not interfere with normal postpartum contraction or involution of the uterus and does not increase the incidence of postpartum hemorrhage.

Following i.m. injection, peak plasma concentration is usually obtained at about 45 minutes, but the range in time is wide. After oral administration, only about 50% of meperidine escapes first-pass metabolism. Peak concentrations in the plasma are usually observed in 1 to 2 hours. Approximately 60% is bound to plasma proteins. Meperidine is metabolized chiefly in the liver. The plasma elimination half-life is normally 3 to 4 hours, but this may be extended considerably in the presence of significant hepatic disease. In patients with cirrhosis, bioavailability may be increased as much as 80%. Meperidine is hydrolyzed to meperidinic acid, which in turn is partially conjugated. Meperidine also undergoes N-demethylation to normeperidine, which may then be hydrolyzed to normeperidinic acid and subsequently conjugated. Normeperidine has a considerably longer plasma elimination half-life (15 to 20 hours) than its parent molecule. In the presence of renal insufficiency, normeperidine elimination is reduced.

At the usual values of urinary pH, or if the urine is alkaline, excretion of unchanged meperidine is negligible; urinary excretion of meperidine and normeperidine is enhanced by acidification of the urine. Meperidine crosses the placenta and appears in milk.

[FONT=Times New Roman, Times, serif]Indications And Clinical Uses:. The relief of moderate to severe pain in many medical, surgical, obstetrical and dental situations.

[FONT=Times New Roman, Times, serif]Contra-Indications:. Hypersensitivity to meperidine. Contraindicated in patients who are receiving MAO inhibitors or those who have received such agents within 14 days. Therapeutic doses of meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. The mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. Some have been characterized by coma, severe respiratory depression, cyanosis and hypotension, and have resembled the syndrome of acute narcotic overdose. In other reactions the predominant manifestations have been hyperexcitability, convulsions, tachycardia, hyperpyrexia and hypertension. Although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reported reactions have occurred with meperidine. If a narcotic is needed in such patients, a sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while the patient's condition and vital signs are under careful observation. (I.V. hydrocortisone or prednisolone have been used to treat severe reactions, with the addition of i.v. chlorpromazine in those cases exhibiting hypertension and hyperpyrexia. The usefulness and safety of narcotic antagonists in the treatment of these reactions is unknown.)

Solutions of meperidine and barbiturates are chemically incompatible.

[FONT=Times New Roman, Times, serif]Manufacturers' Warnings In Clinical States:. Drug Dependence: Meperidine can produce drug dependence of the morphine type and therefore has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of meperidine, and it should be prescribed and administered with the same degree of caution appropriate to the use of morphine. Like other narcotics, meperidine is subject to the provisions of the Narcotic Control Act.

[FONT=Times New Roman, Times, serif]Drug Interactions:. Interactions with Other CNS Depressants: Meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers (see Dosage), sedative-hypnotics (including barbiturates), tricyclic antidepressants, and other CNS depressants (including alcohol). Respiratory depression, hypotension, and profound sedation or coma may result.

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of meperidine and its capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries. In such patients, meperidine must be used with extreme caution and only if its use is deemed essential.

I.V.: If necessary, meperidine may be given i.v., but the injection should be given very slowly, preferably in the form of a diluted solution. Rapid i.v. injection of narcotic analgesics, including meperidine, increases the incidence of adverse reactions; severe respiratory depression, apnea, hypotension, peripheral circulatory collapse, and cardiac arrest have occurred. Meperidine should not be administered i.v. unless a narcotic antagonist and the facilities for assisted or controlled respiration are immediately available. When meperidine is given parenterally, especially i.v., the patient should be lying down.

I.M.: Meperidine should be injected well within the body of a large muscle.

Asthma and Other Respiratory Conditions: Meperidine should be used with extreme caution in patients having an acute asthmatic attack, patients with chronic obstructive pulmonary disease or cor pulmonale, patients having a substantially decreased respiratory reserve, and patients with preexisting respiratory depression, hypoxia, or hypercapnia. In such patients, even usual therapeutic doses of narcotics may decrease respiratory drive while simultaneously increasing airway resistance to the point of apnea.

Hypotensive Effect: The administration of meperidine may result in severe hypotension in the postoperative patient or any individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume or the administration of drugs such as the phenothiazines or certain anesthetics.
 
Blade the first article doesn't address where exactly the stimulator is placed in terms of microstructures of the nerves.

Interesting about the meperidine releasing more histamine. In light of this article, I wonder what the correct answer on a hypothetical test would be...

The nerve stimulator is placed CUTANEOUSLY over the nerve.

Demerol releases LESS Histamine at low doses like those used for PCA or post op shivering, but, more histamine than MSO4 at high doses like tgose used for induction or old Cardiac anesthetic.

100mg of Demerol = 10 mg Mso4. Beyond 100mg Demerol likely to cause more histamine release than MS04 (IMHO).
 
http://journals.lww.com/anesthesiol...ectrode_Polarity_and_Peripheral_Nerve.18.aspx


Read the LANDMARK study on Nerve Stimulators and placement at the wrist.

The Nerve stimulator is usually placed NEXT to the nerve and an action potential is generated by causing a flow of ions through the nerve membrane.

Usually, the Anode (Negative end) is placed distally at the wrist while the Cathode (positive end) is placed more proximally (5-10 cm) on the forearm. Please note the "spread" between Anode and Cathode is MUCH MUCH less important the the DISTAL placement of the Anode (negative).

Blade
 
Thanks for the clarification Blade.

While you are at it, can you explain what exactly apneic oxygenation means? I tried reading it in a few different books and still don't have a good grasp of the concept.

I also had an inquiry about high altitudes and ventilation. From my understanding, at high altitudes low flow ventialtion is not affected at all, while high flows cause a decreased amount of delievered gas. Is that more or less correct? If someone is, let's say in Nepal, post-op on a vent, their flows wouldn't really be affected when compared to someone at sea level b/c 9 times out o10 they will be on low flows....right?
 
Thanks for the clarification Blade.

While you are at it, can you explain what exactly apneic oxygenation means? I tried reading it in a few different books and still don't have a good grasp of the concept.

I also had an inquiry about high altitudes and ventilation. From my understanding, at high altitudes low flow ventialtion is not affected at all, while high flows cause a decreased amount of delievered gas. Is that more or less correct? If someone is, let's say in Nepal, post-op on a vent, their flows wouldn't really be affected when compared to someone at sea level b/c 9 times out o10 they will be on low flows....right?


Here is Part 1 to your question. Part 2 later.

Read this landmark study. See how a patient can stay oxygenated at 100% for more than 30 minutes without any ACTIVE ventilation; only oxygen is being passively given via an endotracheal tube. The Ph drops while the Co2 goes way up; but, the oxygen levels remain good.


http://www.core.org.cn/NR/rdonlyres...F1C8DCC-0C4F-49A4-A5A2-05FED162B3F6/0/ps2.pdf

http://journals.lww.com/anesthesiology/Citation/1959/11000/Apneic_Oxygenation_in_Man.7.aspx
 
Here is Part 1 to your question. Part 2 later.

Read this landmark study. See how a patient can stay oxygenated at 100% for more than 30 minutes without any ACTIVE ventilation; only oxygen is being passively given via an endotracheal tube. The Ph drops while the Co2 goes way up; but, the oxygen levels remain good.


http://www.core.org.cn/NR/rdonlyres...F1C8DCC-0C4F-49A4-A5A2-05FED162B3F6/0/ps2.pdf

http://journals.lww.com/anesthesiology/Citation/1959/11000/Apneic_Oxygenation_in_Man.7.aspx

...and Big Blue says 1 HOUR in healthy volunteers, which I think is amazing.
 
Top